Concepts (137)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cytochrome P-450 CYP1A1 | 7 | 2017 | 51 | 1.910 |
Why?
|
| Enzyme Inhibitors | 9 | 2014 | 433 | 1.510 |
Why?
|
| Quinones | 3 | 2016 | 14 | 1.430 |
Why?
|
| Cytochrome P-450 CYP1A2 | 5 | 2017 | 28 | 1.330 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2016 | 122 | 1.250 |
Why?
|
| Flavones | 4 | 2023 | 12 | 0.870 |
Why?
|
| Receptor, erbB-2 | 2 | 2014 | 133 | 0.870 |
Why?
|
| Cytochrome P-450 Enzyme System | 5 | 2023 | 92 | 0.780 |
Why?
|
| Antineoplastic Agents | 4 | 2016 | 803 | 0.740 |
Why?
|
| Naphthoquinones | 1 | 2017 | 36 | 0.590 |
Why?
|
| Anthraquinones | 1 | 2017 | 9 | 0.580 |
Why?
|
| Proto-Oncogene Proteins c-pim-1 | 1 | 2016 | 4 | 0.560 |
Why?
|
| Dioxanes | 1 | 2015 | 11 | 0.540 |
Why?
|
| Quantitative Structure-Activity Relationship | 3 | 2019 | 107 | 0.520 |
Why?
|
| Models, Molecular | 10 | 2019 | 808 | 0.510 |
Why?
|
| Hydrocortisone | 1 | 2015 | 78 | 0.500 |
Why?
|
| Structure-Activity Relationship | 10 | 2016 | 409 | 0.470 |
Why?
|
| Breast Neoplasms | 3 | 2014 | 1502 | 0.450 |
Why?
|
| Alkynes | 1 | 2012 | 50 | 0.410 |
Why?
|
| Ethers | 1 | 2012 | 20 | 0.400 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2013 | 222 | 0.400 |
Why?
|
| Ligands | 6 | 2017 | 349 | 0.390 |
Why?
|
| Molecular Structure | 3 | 2017 | 492 | 0.360 |
Why?
|
| Humans | 22 | 2023 | 37093 | 0.300 |
Why?
|
| Drug Design | 3 | 2017 | 162 | 0.300 |
Why?
|
| Prostatic Neoplasms | 1 | 2016 | 935 | 0.290 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2014 | 59 | 0.290 |
Why?
|
| Neovascularization, Physiologic | 2 | 2014 | 73 | 0.280 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2006 | 27 | 0.280 |
Why?
|
| Protein Binding | 3 | 2017 | 972 | 0.270 |
Why?
|
| Coumarins | 2 | 2019 | 38 | 0.260 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2005 | 112 | 0.260 |
Why?
|
| Enzyme Activators | 1 | 2003 | 12 | 0.230 |
Why?
|
| Protein Kinase C | 1 | 2003 | 120 | 0.210 |
Why?
|
| Substrate Specificity | 3 | 2017 | 212 | 0.210 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2016 | 1039 | 0.200 |
Why?
|
| Nicotine | 1 | 2023 | 257 | 0.190 |
Why?
|
| Catalytic Domain | 4 | 2014 | 109 | 0.190 |
Why?
|
| Metabolic Detoxication, Phase I | 1 | 2019 | 2 | 0.170 |
Why?
|
| Xenobiotics | 1 | 2019 | 11 | 0.170 |
Why?
|
| Drug Screening Assays, Antitumor | 2 | 2016 | 113 | 0.160 |
Why?
|
| Binding Sites | 4 | 2014 | 651 | 0.150 |
Why?
|
| Liver | 2 | 2017 | 479 | 0.150 |
Why?
|
| Pterocarpans | 1 | 2017 | 21 | 0.150 |
Why?
|
| Estradiol | 2 | 2017 | 262 | 0.150 |
Why?
|
| Enzyme Assays | 1 | 2017 | 12 | 0.150 |
Why?
|
| Osteogenesis | 1 | 2017 | 35 | 0.140 |
Why?
|
| Phenylalanine | 1 | 2017 | 25 | 0.140 |
Why?
|
| Osteoporosis | 1 | 2017 | 34 | 0.140 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2017 | 83 | 0.140 |
Why?
|
| Bone Marrow Cells | 1 | 2017 | 81 | 0.140 |
Why?
|
| Mesenchymal Stem Cells | 1 | 2017 | 62 | 0.140 |
Why?
|
| Steroid 21-Hydroxylase | 1 | 2015 | 2 | 0.140 |
Why?
|
| Steroid 11-beta-Hydroxylase | 1 | 2015 | 3 | 0.140 |
Why?
|
| Steroid 17-alpha-Hydroxylase | 1 | 2015 | 10 | 0.130 |
Why?
|
| Lipid Metabolism | 1 | 2017 | 119 | 0.130 |
Why?
|
| Patents as Topic | 1 | 2015 | 14 | 0.130 |
Why?
|
| NADP | 2 | 2014 | 38 | 0.130 |
Why?
|
| Stem Cells | 1 | 2017 | 141 | 0.130 |
Why?
|
| Adipose Tissue | 1 | 2017 | 177 | 0.130 |
Why?
|
| Cell Line, Tumor | 4 | 2016 | 2231 | 0.130 |
Why?
|
| Hydrogen Bonding | 2 | 2012 | 132 | 0.120 |
Why?
|
| Thiazoles | 1 | 2014 | 74 | 0.120 |
Why?
|
| Protein Structure, Tertiary | 2 | 2005 | 408 | 0.110 |
Why?
|
| Rats | 2 | 2012 | 3483 | 0.110 |
Why?
|
| High-Throughput Screening Assays | 1 | 2013 | 65 | 0.110 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2013 | 52 | 0.110 |
Why?
|
| Animals | 6 | 2014 | 15081 | 0.110 |
Why?
|
| Time Factors | 1 | 2017 | 1742 | 0.100 |
Why?
|
| Kinetics | 3 | 2014 | 708 | 0.100 |
Why?
|
| Thermodynamics | 1 | 2012 | 216 | 0.100 |
Why?
|
| Oxidative Stress | 1 | 2017 | 938 | 0.100 |
Why?
|
| Estrogen Antagonists | 1 | 2010 | 28 | 0.090 |
Why?
|
| Cell Proliferation | 1 | 2016 | 1198 | 0.090 |
Why?
|
| Computer Simulation | 1 | 2012 | 362 | 0.090 |
Why?
|
| Isoflavones | 1 | 2010 | 129 | 0.090 |
Why?
|
| Estrogens | 1 | 2010 | 202 | 0.080 |
Why?
|
| Female | 4 | 2017 | 20969 | 0.080 |
Why?
|
| Cells, Cultured | 2 | 2017 | 1518 | 0.080 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2006 | 32 | 0.070 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2005 | 9 | 0.070 |
Why?
|
| Umbilical Cord | 1 | 2005 | 14 | 0.070 |
Why?
|
| alpha-Synuclein | 1 | 2006 | 52 | 0.070 |
Why?
|
| tau Proteins | 1 | 2006 | 167 | 0.060 |
Why?
|
| Nitriles | 1 | 2004 | 69 | 0.060 |
Why?
|
| Fluorometry | 2 | 2014 | 17 | 0.060 |
Why?
|
| Parkinson Disease | 1 | 2006 | 178 | 0.060 |
Why?
|
| Quinolines | 1 | 2004 | 64 | 0.060 |
Why?
|
| Lactams | 1 | 2003 | 1 | 0.060 |
Why?
|
| Pyrrolidinones | 1 | 2003 | 7 | 0.060 |
Why?
|
| Radioligand Assay | 1 | 2003 | 66 | 0.060 |
Why?
|
| Binding, Competitive | 1 | 2003 | 111 | 0.060 |
Why?
|
| Dimerization | 1 | 2003 | 112 | 0.060 |
Why?
|
| Carcinogens | 1 | 2023 | 124 | 0.050 |
Why?
|
| Isoenzymes | 1 | 2003 | 161 | 0.050 |
Why?
|
| Endothelial Cells | 1 | 2005 | 308 | 0.050 |
Why?
|
| Calcium | 1 | 2003 | 480 | 0.050 |
Why?
|
| Male | 1 | 2016 | 20025 | 0.040 |
Why?
|
| Signal Transduction | 1 | 2006 | 1908 | 0.040 |
Why?
|
| Phytoestrogens | 1 | 2017 | 38 | 0.040 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2017 | 59 | 0.040 |
Why?
|
| Vascular Diseases | 1 | 2017 | 30 | 0.040 |
Why?
|
| Metabolic Diseases | 1 | 2017 | 33 | 0.030 |
Why?
|
| Nervous System Diseases | 1 | 2017 | 71 | 0.030 |
Why?
|
| Enzyme Activation | 1 | 2017 | 444 | 0.030 |
Why?
|
| Chorioallantoic Membrane | 1 | 2014 | 11 | 0.030 |
Why?
|
| Chick Embryo | 1 | 2014 | 74 | 0.030 |
Why?
|
| Cell Line, Transformed | 1 | 2014 | 91 | 0.030 |
Why?
|
| Proteoglycans | 1 | 2014 | 47 | 0.030 |
Why?
|
| Laminin | 1 | 2014 | 61 | 0.030 |
Why?
|
| Microfilament Proteins | 1 | 2014 | 69 | 0.030 |
Why?
|
| Drug Combinations | 1 | 2014 | 98 | 0.030 |
Why?
|
| Cell Differentiation | 1 | 2017 | 587 | 0.030 |
Why?
|
| Collagen | 1 | 2014 | 172 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2014 | 251 | 0.030 |
Why?
|
| Molecular Dynamics Simulation | 1 | 2014 | 133 | 0.030 |
Why?
|
| Neoplasm Metastasis | 1 | 2014 | 219 | 0.030 |
Why?
|
| Small Molecule Libraries | 1 | 2013 | 45 | 0.030 |
Why?
|
| Data Interpretation, Statistical | 1 | 2013 | 111 | 0.030 |
Why?
|
| Carrier Proteins | 1 | 2014 | 305 | 0.030 |
Why?
|
| Spectrometry, Fluorescence | 1 | 2013 | 208 | 0.030 |
Why?
|
| Crystallography, X-Ray | 1 | 2012 | 265 | 0.020 |
Why?
|
| Cell Movement | 1 | 2014 | 571 | 0.020 |
Why?
|
| Response Elements | 1 | 2010 | 56 | 0.020 |
Why?
|
| Receptors, Progesterone | 1 | 2010 | 81 | 0.020 |
Why?
|
| Estrogen Receptor alpha | 1 | 2010 | 111 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2010 | 337 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2010 | 259 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 2010 | 578 | 0.020 |
Why?
|
| United States | 1 | 2017 | 4223 | 0.020 |
Why?
|
| Neoplasms | 1 | 2017 | 1103 | 0.020 |
Why?
|
| Spectrometry, Mass, Fast Atom Bombardment | 1 | 2006 | 7 | 0.020 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2006 | 289 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2006 | 928 | 0.010 |
Why?
|
| Middle Aged | 1 | 2017 | 10129 | 0.010 |
Why?
|
| Adult | 1 | 2017 | 11712 | 0.010 |
Why?
|
| Mice | 1 | 2010 | 5913 | 0.010 |
Why?
|